NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
Clinical Trials
16 trialsNCT05031494 2025-01-06
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Completed
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT04879654 2024-03-05
SNMM
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting
NCT04137900 2024-02-05
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Unknown
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05451407 2023-07-07
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05907512 2023-06-22
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
Fudan University
Phase 2 Unknown
NCT05478473 2023-06-18
Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT05723432 2023-04-27
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT05539118 2022-09-14
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
Xijing Hospital
Phase 1/2 Not yet recruiting
NCT04773951 2021-08-24
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT04884997 2021-05-13
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT04197882 2021-02-10
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT04072900 2020-04-28
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Phase 1 Unknown
NCT04234620 2020-01-21
Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .
Shanghai Junshi Bioscience Co., Ltd.
Unknown